Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
78.65B
Market cap78.65B
Price-Earnings ratio
18.30
Price-Earnings ratio18.30
Dividend yield
0.47%
Dividend yield0.47%
Average volume
536.97K
Average volume536.97K
High today
$757.60
High today$757.60
Low today
$734.56
Low today$734.56
Open price
$751.22
Open price$751.22
Volume
672.28K
Volume672.28K
52 Week high
$821.11
52 Week high$821.11
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

With a market cap of 78.65B, Regeneron(REGN) trades at $741.78. The stock has a price-to-earnings ratio of 18.30 and currently yields dividends of 47.2%.

On 2026-03-19, Regeneron(REGN) stock traded between a low of $734.56 and a high of $757.60. Shares are currently priced at $741.78, which is +1.0% above the low and -2.1% below the high.

The Regeneron(REGN)'s current trading volume is 672.28K, compared to an average daily volume of 536.97K.

During the past year, Regeneron(REGN) stock moved between $476.49 at its lowest and $821.11 at its peak.

During the past year, Regeneron(REGN) stock moved between $476.49 at its lowest and $821.11 at its peak.

REGN News

Nasdaq 3h
Formycon Secures Europe Launch Timing For FYB203 After Regeneron, Bayer Settlement

(RTTNews) - Formycon AG (FYB.DE, FYBGF), an independent German biotechnology company, on Thursday announced that it entered into a settlement and license agreem...

Formycon Secures Europe Launch Timing For FYB203 After Regeneron, Bayer Settlement
TipRanks 3d
Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease

Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. The study “A Double-blinded Extension Study to Evaluate...

Simply Wall St 5d
Regeneron Pharmaceuticals Valuation Check After Recent Share Price Cooling

Advertisement Regeneron Pharmaceuticals stock: context behind recent moves Regeneron Pharmaceuticals (REGN) shares have seen mixed returns recently, with a 1...

Regeneron Pharmaceuticals Valuation Check After Recent Share Price Cooling

Analyst ratings

73%

of 30 ratings
Buy
73.3%
Hold
26.7%
Sell
0%

More REGN News

The Motley Fool 5d
Is Eli Lilly's Weight Loss Empire in Trouble?

Over the past two years, Eli Lilly (LLY +0.80%) has established itself as the leader in the weight loss market. That's thanks to the company's tirzepatide, a co...

Is Eli Lilly's Weight Loss Empire in Trouble?
TipRanks 7d
Dupilumab Study Tracks Mental Health Benefits in Atopic Dermatitis Patients Across Gulf Countries

Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. The Impact of Dupilumab Treatment on Anxiety and Depress...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.